These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
To be a Tilray Brands shareholder, you have to believe in the company’s ability to expand its U.S. addressable market as regulations and consumer demand evolve. The August launch of new hemp-derived Delta-9 drinks adds excitement, but any change in federal cannabis policy remains the primary short-term catalyst and risk, until federal reform truly materializes, the business impact is limited.
Among recent announcements, the July earnings report stands out: Tilray posted a much larger net loss and a sizeable impairment charge, further highlighting ongoing profitability challenges. For investors tracking regulatory developments, these financial results cement why potential U.S. reform could matter so much to the bottom line.
By contrast, investors should note unresolved issues around operating profitability, especially as recent impairment and net loss figures suggest…
Read the full narrative on Tilray Brands (it's free!)
Tilray Brands' narrative projects $940.4 million revenue and $193.4 million earnings by 2028. This requires 4.6% yearly revenue growth and a $2.4 billion increase in earnings from -$2.2 billion.
Uncover how Tilray Brands' forecasts yield a $0.928 fair value, in line with its current price.
Simply Wall St Community members set fair values for Tilray Brands ranging from US$0.93 to US$44.45 based on 17 unique analyses. With persistent net losses and a shrinking addressable market still top of mind, you can see why opinions differ so widely.
Explore 17 other fair value estimates on Tilray Brands - why the stock might be worth just $0.928!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com